WaferGen's Q1 Revenues Drop Sharply | GenomeWeb

NEW YORK (GenomeWeb News) – WaferGen Biosystems' revenues for the first quarter of 2012 fell nearly five-fold year over year, the company said in its Form 10-Q filed on Friday with the US Securities and Exchange Commission.

During the three months ended March 31, the Fremont, Calif.-based firm recorded $73,233 in revenues, down from $351,032 a year ago. The sharp dropoff was due to "the absence of sales" of any SmartChip Real-Time PCR Systems in the recently ended quarter, compared to one sale a year ago, WaferGen said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.